One of the most shocking realities is just how little clinical trial data from pharmaceutical companies is truly accessible to independent researchers. Despite the public perception that rigorous data review and transparency are standard, the system is riddled with secrecy and obstacles. Most clinical data is tightly controlled, often shielded by corporate interests, non-disclosure agreements, and regulatory loopholes. Even when trial results are published, they are often incomplete, selectively reported, or presented in ways that obscure negative outcomes and side effects. Attempts by outsiders to access raw data are routinely stonewalled, with excuses ranging from proprietary concerns to national security. This lack of transparency enables manipulation and protects the interests of the industry over public health. If you want to understand how deep this rabbit hole goes and how these practices impact everything from drug safety to public trust, you need to hear the full discussions and revelations in the podcast episodes. The truth is far more disturbing than you might think—listen in to get the whole picture.